Global Glycomics / Glycobiology Market Outlook 2028

Ongoing Research Report

In the News
July 2018: Agilent Technologies Inc. announced the completed acquisition of the leading provider of chemical standards and certified reference materials, ULTRA Scientific, Inc. and all its business assets.

February 2018: Merck KGaA announced that it has invested around USD 47 million additionally for building a robust manufacturing and distribution platform in the field of biopharmaceuticals and other products of its portfolio in South Korea, India and China in the Asia Pacific region.

Introduction to Glycomics / Glycobiology

Glycobiology is termed as the study of entire biology that includes structure and function of molecules containing carbohydrates (sugar and saccharides) also known as glycans. It is widely accepted in biotechnological research and biomedicine. Glycans or carbohydrates are among the fundamental classes of macromolecules present in biological systems and are formed by individual sugar units called monosaccharides that are linked to each other in multiple ways. Carbohydrates are responsible to control all aspects of cellular processing that involves cell-cell interactions, adhesion mechanisms, regulating hormonal activity, signaling for growth factors, blood clotting, and it also directs embryonic development. Glycomics is referred to the study of glycomes and it also includes the information of physiologic, genetic, pathologic, and other aspects. The term, which is a subset of glycobiology, also includes the systematic study of all glycan structures of a given cell type or organism.

Market Size and Forecast

The global glycomics / glycobiology market is projected to witness significant growth over the forecast period on account of escalating research & development expenditure by pharmaceutical companies coupled with an increment of chronic diseases such as cancer and diabetes. According to the World Health Organization, the global cancer burden raised to 18.1 million cases and 9.6 million deaths in 2018, and approximately 70% of deaths from cancer occur in low-income and middle-income countries. Additionally, factors such as availability of products to conduct protocol with high specificity and sensitivity, funding through government bodies, and continuous technological advancements are estimated to support the development of the glycomics / glycobiology market over the forecast period.

The glycomics / glycobiology market is anticipated to register a notable CAGR over the forecast period i.e. 2020-2028. The market is segmented by product, by application & end-user, out of which, the enzymes segment of product sector is anticipated to hold leading shares in the glycomics / glycobiology market on account of consumable nature of enzymes and their wide applications in a variety of R&D and drug discovery procedures. On the contrary, the drug discovery & delivery segment of application sectors is estimated to register a robust growth to the increasing R&D investments in pharmaceutical and biotechnology companies coupled with the rising number of drug discovery research activities in academic research institutes.

Growth Drivers

Proliferating Cancer and Diabetic Diseases To Drive the Market Growth

Increment in diseases such as cancer and diabetes are the major factor fueling the glycomics / glycobiology market. According to the World Health Organization, one in every 5 men and one in every 6 women worldwide develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease. Additionally, continuous technological advancements, rising research & development expenditure by pharmaceutical companies, rising funding through government bodies, and availability of products to conduct protocol with high specificity and sensitivity are anticipated to drive the global glycomics / glycobiology market over the forecast period.

By Region

Based on geographically, the glycomics / glycobiology market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.

North America is expected to hold the largest share of the global market, followed by Europe. The leading share of the glycomics / glycobiology market in North America can be attributed to the increasing investments in glycomics / glycobiology research, presence of all key players, along with the rising R&D investments in pharmaceutical companies for drug discovery. On the contrary, Asia Pacific is projected to witness modest growth during the forecast period owing to untapped market opportunities. Evolving pharmaceutical and biopharmaceutical industries have resulted in the immense growth of glycomics / glycobiology in the region. Moreover, investments by Contract Research Organizations (CROs) for the development and production of drugs and biologics are expected to drive the growth of the Asia Pacific glycomics / glycobiology market over the forecast period.

The glycomics / glycobiology market is further classified on the basis of region as follows:

• North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
• The Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Please note this is an ongoing research and will be delivered 8-9 working days after order confirmation. The TOC can be also be requested.